Navigation Links
ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
Date:9/27/2010

scores were recorded prior to the first treatment with REMURA and were compared to scores at Day 14, Day 42 and Day 52.

Authors of the posters were Simon P. Chandler, Ph.D., James A. Gow, M.D. and Timothy R. McNamara, Pharm.D. of ISTA Pharmaceuticals, Inc., Irvine, CA, USA; Sheri L. Rowen, M.D., of the Mercy Medical Eye and Cosmetic Surgery Center, Baltimore, MD, USA; and Neal A. Sher, M.D., F.A.C.S., Partner, Eye Care Associates, Minneapolis, MN, USA.

ISTA recently announced the Company has initiated its REMURA Phase 3 clinical study program.  Two Phase 3 studies to evaluate the efficacy and safety of REMURA are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA), and two remaining Phase 3 safety studies are the subject of additional SPAs currently under review by the FDA.  ISTA anticipates starting the remaining safety studies later this year and reporting results for the first two Phase 3 efficacy and safety studies in the middle of 2011.

ABOUT DRY EYE DISEASE

Dry eye occurs when there is an imbalance of tears that provides moisture and lubrication to the eye, which can result in pain, itching, redness, blurry vision, light sensitivity and/or a gritty sensation or feeling of sand in the eye.  Causes for dry eye include environmental conditions such as air conditioning, smoke and dust, aging and menopause, side-effects from antihistamines and birth control pills, Sjogren's syndrome, rheumatoid arthritis and structural problems with the eye lid's ability to close. Left untreated, dry eye can lead to abrasions on the surface of the eye and damage to the cornea. Current treatments include artificial tears and ointments, topical steroids, a topical immunomodulator that is the only approved prescription eye drop treatment, and punctal occlusion (closing or plugging of tear drains).  

ABOUT REMURA AND BROMFENAC OPHTHALMIC SOLUTION'/>"/>

SOURCE ISTA Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
2. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
3. TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
6. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
7. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
8. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
9. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
10. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
11. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 Alpha ... distributor , will be exhibiting for the 13th ... of Medical Instrumentation (AAMI) 2013 Conference and Expo. ... support, distribute, and manufacture healthcare technologies. This year’s ... Long Beach, California. , The three-day event ...
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... The Wisconsin Technology Council is taking applications for the ... quite likely hundreds of them will vie ... two years' grand-prize winners have been life-science companies, but ... and information technology. , ,All 2004 and 2005 finalists ...
... statewide online high-school program may close unless administrators can ... on initial expectations, the Milwaukee Journal-Sentinel reports. ... for the Waukesha school district where it is operated ... to have a net loss of $1.2 million by ...
... place this past week at the University of Chicagos Gleacher ... the meeting was an opportunity to hear from four individuals, ... meetings in different cities, as a preview to what we ... Biotechnology meeting comes to Chicago in April, 2006. , ,Some ...
Cached Biology Technology:The legacy of BIO 2006, what it will be and how we need to plan for it now 2The legacy of BIO 2006, what it will be and how we need to plan for it now 3The legacy of BIO 2006, what it will be and how we need to plan for it now 4The legacy of BIO 2006, what it will be and how we need to plan for it now 5The legacy of BIO 2006, what it will be and how we need to plan for it now 6
(Date:5/22/2013)... (NLST) investigators also conclude that the 20 percent ... tomography (LDCT) versus chest X-ray (CXR) screening previously ... at experienced screening centers in the United States. ... with their patients about the benefits and risks ... in the New England Journal of Medicine ...
(Date:5/22/2013)... must join together in a major new effort to ... in providing Earth,s people with clean water that looms ... a comment article in the current edition of ... the American Chemical Society (ACS), the world,s largest scientific ... Ph.D., and Jerald L. Schnoor, Ph.D., explain that shortages ...
(Date:5/22/2013)... human health effects from disposal of millions of ... to recommend stronger government policies to encourage recovery, ... That,s the conclusion of a new paper in ... . , Oladele A. Ogunseitan and colleagues point ... powering everything from smart phones to components in ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... a vital link in the chain of events that gives ... Wellcome Trust Centre for Stem Cell Research at the University ... process that gives embryonic stem cells their unique ability to ... the body (from liver cells to skin cells). Their findings, ...
... MADISON Success in soccer sometimes comes with "bending ... occurs at the moment of conception and when nerve ... bent before the merging process can begin, University of ... first concrete evidence that a protein called synaptotagmin plays ...
... protein production, a Princeton-led team has discovered why certain ... they also have discovered how one protein protects against ... In a study appearing in the Aug. 7 ... Princeton,s Warner-Lambert Parke-Davis Professor of Molecular Biology, and Johna ...
Cached Biology News:Switching on the power of stem cells 2A new 'bent' on fusion 2Princeton team learns why some drugs pack such a punch 2Princeton team learns why some drugs pack such a punch 3
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
... belongs to the family of calcium binding proteins ... is composed of an alpha and beta chain ... S100 protein is also expressed in the ... in skin and interdigitating reticulum cells in the ...
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Biology Products: